JP2022523668A5 - - Google Patents

Info

Publication number
JP2022523668A5
JP2022523668A5 JP2021542518A JP2021542518A JP2022523668A5 JP 2022523668 A5 JP2022523668 A5 JP 2022523668A5 JP 2021542518 A JP2021542518 A JP 2021542518A JP 2021542518 A JP2021542518 A JP 2021542518A JP 2022523668 A5 JP2022523668 A5 JP 2022523668A5
Authority
JP
Japan
Prior art keywords
saturated monocyclic
monocyclic heterocycle
member saturated
dyskinesia
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015083 external-priority patent/WO2020154683A1/en
Publication of JP2022523668A publication Critical patent/JP2022523668A/ja
Publication of JP2022523668A5 publication Critical patent/JP2022523668A5/ja
Pending legal-status Critical Current

Links

JP2021542518A 2019-01-25 2020-01-24 Magl阻害剤による疾病の治療方法 Pending JP2022523668A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796941P 2019-01-25 2019-01-25
US62/796,941 2019-01-25
PCT/US2020/015083 WO2020154683A1 (en) 2019-01-25 2020-01-24 Methods of treating disease with magl inhibitors

Publications (2)

Publication Number Publication Date
JP2022523668A JP2022523668A (ja) 2022-04-26
JP2022523668A5 true JP2022523668A5 (enExample) 2023-01-20

Family

ID=71736532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542518A Pending JP2022523668A (ja) 2019-01-25 2020-01-24 Magl阻害剤による疾病の治療方法

Country Status (15)

Country Link
US (1) US20220110933A1 (enExample)
EP (1) EP3914589A4 (enExample)
JP (1) JP2022523668A (enExample)
KR (1) KR20210120020A (enExample)
CN (1) CN113330005A (enExample)
AU (1) AU2020212596A1 (enExample)
BR (1) BR112021014402A2 (enExample)
CA (1) CA3125636A1 (enExample)
CL (1) CL2021001922A1 (enExample)
IL (1) IL284791A (enExample)
MA (1) MA54827A (enExample)
MX (1) MX2021008865A (enExample)
SG (1) SG11202108008PA (enExample)
WO (1) WO2020154683A1 (enExample)
ZA (1) ZA202104709B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210010475A (ko) 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제
KR20220101095A (ko) * 2019-11-15 2022-07-19 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049332A1 (en) * 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US9487495B2 (en) * 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
ES2878041T3 (es) * 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
DK3541807T3 (da) * 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
EP3571202B1 (en) * 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
KR20210010475A (ko) * 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제

Similar Documents

Publication Publication Date Title
JP2022523668A5 (enExample)
JP2022509091A5 (enExample)
JP2015509534A5 (enExample)
JP2016534063A5 (enExample)
JP2018070614A5 (enExample)
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
JP2013010792A5 (enExample)
JP2024516371A5 (enExample)
JP2018518537A5 (enExample)
JP2022191257A5 (enExample)
JP2019524883A5 (enExample)
JP2015509535A5 (enExample)
CN104010636B (zh) 三环化合物、包含它们的组合物及其用途
EA202090987A1 (ru) Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона
JP2020507589A5 (enExample)
JP2019527234A5 (enExample)
AU2016302243A1 (en) Beta-substituted Beta-amino acids and analogs as chemotherapeutic agents and uses thereof
BR112015026410B1 (pt) Derivados de dolastatina 10 e auristatinas, seu uso, sua composição farmacêutica e seus métodos para preparação
JP2013540776A5 (enExample)
CN111801013B (zh) 小分子核受体调节剂的酰胺前药
JP2017522304A5 (enExample)
JP2015535247A5 (enExample)
JP2021534160A5 (enExample)
JP2007504235A5 (enExample)
JP7471685B2 (ja) 新規な化合物およびそれを含むがんの予防または治療用薬学組成物